Clear Street Reaffirms Their Buy Rating on Y-Mabs Therapeutics (YMAB)
Clear Street analyst William Maughan reiterated a Buy rating on Y-Mabs Therapeutics (YMAB – Research Report) today and set a price target of $17.00. The company's shares closed today at $4.62.
Confident Investing Starts Here:
Maughan covers the Healthcare sector, focusing on stocks such as Y-Mabs Therapeutics, Delcath Systems, and Summit Therapeutics. According to TipRanks, Maughan has an average return of 18.5% and a 49.37% success rate on recommended stocks.
In addition to Clear Street, Y-Mabs Therapeutics also received a Buy from H.C. Wainwright's Robert Burns in a report issued on May 19. However, on May 13, Morgan Stanley maintained a Sell rating on Y-Mabs Therapeutics (NASDAQ: YMAB).
Based on Y-Mabs Therapeutics' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $20.9 million and a GAAP net loss of $5.2 million. In comparison, last year the company earned a revenue of $19.93 million and had a GAAP net loss of $6.63 million
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of YMAB in relation to earlier this year. Most recently, in March 2025, Thomas Gad, the CBO of YMAB sold 10,810.00 shares for a total of $56,536.30.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent
- Composition of matter patent affirmed, provides protection into 2030 - Builds on recent ruling in favor of Acadia for formulation patent expiring in 2038 SAN DIEGO, June 09, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID® (pimavanserin) '740 composition of matter patent. The affirmance came in Acadia's litigation against MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc. In its affirmance, the Appeals Court applied the precedent established in Allergan USA, Inc. v. MSN Laboratories Private Ltd., MSN Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, holding that "a first filed, first-issued, later-expiring claim cannot be invalidated by a later-filed, later-issued, earlier-expiring reference claim having a common priority date." "We are gratified that the U.S. Federal Appeals Court has affirmed the lower court's ruling in favor of our composition of matter patent for NUPLAZID, securing protection into 2030 for this patent, and beyond based on the recent favorable ruling for our formulation patent providing patent protection for NUPLAZID 34 mg capsule formulation into 2038," said Catherine Owen Adams, Chief Executive Officer. "These decisions reinforce our commitment to safeguarding the intellectual property that underpins our innovations in addressing serious, unmet medical needs." This follows the U.S. District Court for the District of Delaware ruling in favor of Acadia regarding its '721 formulation patent for NUPLAZID which ruled in favor of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA (Abbreviated New Drug Application) filers. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential," "continue" and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) the impact of the court ruling on our business and our ability to defend ourselves in the future; (ii) the continued patent protection for NUPLAZID; and (iii) the anticipated timing for termination of such protections. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our ability to maintain, protect and enhance our intellectual property; the outcome of other existing and potential future lawsuits challenging our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-Q for the quarter ended March 31, 2025 as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law. View source version on Contacts Investor Contacts: Acadia Pharmaceuticals Kildani(858) 261-2872ir@ Acadia Pharmaceuticals Tieszen(858) 261-2950ir@ Media Contact: Acadia Pharmaceuticals Kazenelson(818) 395-3043media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Inflation Cools, Jobs Steady--Is This the Market Rebound Investors Have Been Waiting For?
Consumer anxiety about rising prices may finally be easingand the timing could matter. According to fresh data from the New York Fed, Americans now see inflation coming in lower than they did just a month ago. Median year-ahead expectations dropped to 3.2% in May, down from 3.6% in April. Three- and five-year views also edged lower, now sitting at 3.0% and 2.6%, respectively. The shift follows a temporary de-escalation in trade tensions, with President Trump agreeing to reduce tariffs on Chinese imports. That announcement, while short-term, may have helped reverse the negative consumer sentiment that had been building since early this year. The job picture isn't boomingbut it might be stabilizing. Americans' perceived risk of losing their job over the next year ticked slightly lower, and more people say they feel confident enough to quit voluntarily. That's typically a positive signal for labor markets. At the same time, the share of households saying they expect to be financially worse off in a year has shrunk, and fewer respondents report difficulty accessing credit. Perhaps more telling: the average probability of missing a loan payment has dropped to its lowest point since Januaryhinting at some relief from financial stress, even as parts of the economy remain under pressure. This shift in sentiment may be influencing how people see the market. More consumers now expect the U.S. stock market to be higher a year from now. That optimism, combined with cooler inflation expectations and fewer job fears, could support short-term risk appetite heading into the summer. The Federal Reserve is widely expected to keep rates on pause at its upcoming June 1718 meeting, giving markets more room to digest the macro shifts. Tesla (NASDAQ:TSLA) and other high-beta names might see increased investor interest if this rebound in consumer confidence translates into steadier flows into equities. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
See the Incredible Returns If You Invested in 10 of the Top Performing Stocks Over the Last 5 Years (Including GameStop)
Volatility is no fun if you're a stock market investor — and there's been plenty of that so far in 2025. But it's important to keep in mind that stocks in general have always produced strong returns over time. The S&P 500 has risen by about 91% over the past five years alone, despite major headwinds ranging from COVID-19 and soaring inflation to President Donald Trump's current tariff threats. The Dow is up about 62% over the same time frame, while the Nasdaq has roughly doubled in value. Discover More: Find Out: Those are all very good returns, but they pale in comparison to the best performing stocks. If you were fortunate enough to invest in one of those, you would have seen your money rise more than 10-fold in the last half-decade. One reason some of the best performers rose so fast is that they traded at very low values five years ago — in some cases around $1 a share. Any spike in value would represent a major percentage gain. An example is GameStop, the gaming and entertainment company whose stock could be purchased for a little more than $1 a share in June 2020. GameStop grabbed headlines in early 2021 when professional investors shorted the stock, figuring it would go down in value. But as EBSCO noted at the time, a 'wave' of amateur investors started buying up shares and helped the stock soar by more than 1,500% in a matter of weeks. Today, GameStop trades for around $30 a share. If you had invested $100 in the company in early June of 2020, your investment would now be worth more than $2,500. Here's a look at the massive returns you would have gotten by investing in 10 of the top performing stocks over the past five years. Each has risen by at least 1,000% and boasts a current price of roughly $30 a share or more. Trending Now: Closing price June 8, 2020: $3.10 per share Closing price June 4, 2020: $132.41 5-year return: 4,171% Closing price June 8, 2020: $1.25 Closing price June 4, 2020: $44.97 5-year return: 3,498% Closing price June 8, 2020: $11.80 Closing price June 4, 2020: $378.10 5-year return: 3,104% Closing price June 8, 2020: $1.18 Closing price June 4, 2020: $29.95 5-year return: 2,438% Closing price June 8, 2020: $3.97 Closing price June 4, 2020: $84.89 5-year return: 2,038% Closing price June 8, 2020: $10.51 Closing price June 4, 2020: $193.81 5-year return: 1,744% Closing price June 8, 2020: $6.57 Closing price June 4, 2020: $119.90 5-year return: 1,725% Closing price June 8, 2020: $5.35 Closing price June 4, 2020: $91.66 5-year return: 1,613% Closing price June 8, 2020: $2.71 Closing price June 4, 2020: $46.16 5-year return: 1,603% Closing price June 8, 2020: $10.37 Closing price June 4, 2020: $122.82 5-year return: 1,084% More From GOBankingRates 3 Luxury SUVs That Will Have Massive Price Drops in Summer 2025 8 Common Mistakes Retirees Make With Their Social Security Checks 10 Cars That Outlast the Average Vehicle This article originally appeared on See the Incredible Returns If You Invested in 10 of the Top Performing Stocks Over the Last 5 Years (Including GameStop)
